Lee Gray’s Post

Join me on April 23 to hear perspectives from top clinical research experts and disease area specialists on Alzheimer’s Disease (AD) and Multiple Sclerosis (MS) treatments. 🧠 Learn about development challenges in each, how they were overcome, and the shared lessons that can propel novel approaches to more effective clinical trials.   Register now to secure your spot and join in this innovative conversation! #Alzheimers #MultipleSclerosis #ClinicalTrials #Biotech

Join me on April 23 to hear perspectives from top clinical research experts and disease area specialists on Alzheimer’s Disease (AD) and Multiple Sclerosis (MS) treatments. 🧠 Learn about development challenges in each, how they were overcome, and the shared lessons that can propel novel approaches to more effective clinical trials.   Register now to secure your spot and join in this innovative conversation! #Alzheimers #MultipleSclerosis #ClinicalTrials #Biotech

Join me on April 23 to hear perspectives from top clinical research experts and disease area specialists on Alzheimer’s Disease (AD) and Multiple Sclerosis (MS) treatments. 🧠 Learn about development challenges in each, how they were overcome, and the shared lessons that can propel novel approaches to more effective clinical trials.   Register now to secure your spot and join in this innovative conversation! #Alzheimers #MultipleSclerosis #ClinicalTrials #Biotech

🧠💊 Exploring New Frontiers in Alzheimer's Treatment: In our latest article, we break down how we can tackle the complexity of multi-targeted drug discovery for Alzheimer's. This approach aims to address multiple aspects of the disease simultaneously, paving the way for more effective treatments. Join us on this journey towards medical advancement! #Alzheimers #MedicalInnovation #Science https://lnkd.in/ddaGtgSg

Alzheimer’s Disease Scientists/Researcher’s Could human iPSCs help us to tackle the 99.6% failure rate for Alzheimer's Disease drug discovery? In this excerpt from our webinar "Tackling the Alzheimer's 99.6% problem", our Product Manager Dr Jan Turner explains the challenges for Alzheimer's Disease (AD) drug discovery. Our vision is to develop an AD "clinical trial in a dish" model comprising a large, diverse collection of patient samples to increase statistical power and enable patient stratification. To hear more about this, access the full webinar recording here: https://hubs.la/Q02xxm6Q0 #CNS #humancells #research #drugdiscovery #drugdevelopment #neuroscience #biopharma #biotech #pharma

And now we have two. The FDA has granted full approval to Eli Lilly & Co.'s Alzheimer's treatment Kisunla, making it the second anti-amyloid treatment to get the agency's full imprimatur. But finally getting treatments across the finish line is not the same as getting treatments to the millions of people in the US with the neurodegenerative disease. This roll out will be complex. The challenge was reflected in the discussion amongst FDA's expert advisors, who met last month to review Kisunla. They focused less on whether the drug worked-- they all seemed to agree it did--but for whom it worked and how it should be used. Their discussion was an important reminder of the challenge of getting these anti-amyloid drugs to the people that will most benefit, as well as the many open questions about how best to use them. Read more in my recent Bloomberg Opinion column:

Eli Lilly and Company’s Kisunla (donanemab-azbt) Receives Approval in China to Treat Early Symptomatic Alzheimer's Disease #elililly #kinsula #nmpa #alzheimersdisease #regulatory

Could human iPSCs help us to tackle the 99.6% failure rate for Alzheimer's Disease drug discovery? In this excerpt from our webinar "Tackling the Alzheimer's 99.6% problem", our Product Manager Dr Jan Turner explains the challenges for Alzheimer's Disease (AD) drug discovery. Our vision is to develop an AD "clinical trial in a dish" model comprising a large, diverse collection of patient samples to increase statistical power and enable patient stratification. To hear more about this, access the full webinar recording here: https://hubs.la/Q02xxm6Q0 #iPSCs #AlzheimersDisease #ClinicalTrialInADish #PatientStratification #StemCells

MedNews from Medical and Pharma Insider: IGC Pharma closes $3 Million private placement to advance Alzheimer's treatment https://wix.to/Z8cnRPJ MedNews is a program of Medical and Pharma Insider

Stay in the know about RSO! 🙌 @budtender_jazz breaks down this full-spectrum cannabis extract. RSO has grown in popularity for potential therapeutic benefits to include: chronic pain management, cancer-related symptoms, and insomnia. As interest in alternative therapies grows for cancer and chronic conditions, scientifically understanding its potential uses in modern medicine increases in importance. Click the link in our bio to read more about the history and uses of RSO, while considering its legality, safety, and use guidance.